국내 CNS 1위 명인제약 ‘고배당·매출성장’ 두토끼 포석

Myungin Pharmaceutical's appointment of an R&D-focused CEO and commitment to double-digit research investment while maintaining 25%+ dividends challenges the false choice between innovation and shareholder returns in pharmaceutical strategy. This strategic shift signals the Korean pharmaceutical industry's broader transition from mature product monetization to innovation-driven growth, particularly critical as CNS drug markets intensify competition. For investors and industry stakeholders, the company's dual-axis approach offers a blueprint for how established pharma companies can achieve sustainable global competitiveness.